Synonym
Fluorophene; Fluorosalan; Fluorsalan; Flusalan; NSC 166520; NSC-166520; NSC166520; Vancide FP; WR 78550; WR78550; WR-78550;
IUPAC/Chemical Name
3,5-Dibromo-3'-(trifluoromethyl)salicylanilide
InChi Key
VYKKDKFTDMVOBU-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H8Br2F3NO2/c15-8-5-10(12(21)11(16)6-8)13(22)20-9-3-1-2-7(4-9)14(17,18)19/h1-6,21H,(H,20,22)
SMILES Code
Oc1c(Br)cc(Br)cc1C(=O)Nc2cccc(c2)C(F)(F)F
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Nuclear factor-kappa B (NF-kappaB) is a transcription factor that plays a critical role across many cellular processes including embryonic and neuronal development, cell proliferation, apoptosis, and immune responses to infection and inflammation. Dysregulation of NF-kappaB signaling is associated with inflammatory diseases and certain cancers. Constitutive activation of NF-kappaB signaling has been found in some types of tumors including breast, colon, prostate, skin and lymphoid, hence therapeutic blockade of NF-kappaB signaling in cancer cells provides an attractive strategy for the development of anticancer drugs
Preparing Stock Solutions
The following data is based on the
product
molecular weight
439.03
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, Van Leer D, Leister W, Austin CP, Xia M. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol. 2010 May 1;79(9):1272-80. doi: 10.1016/j.bcp.2009.12.021. Epub 2010 Jan 11. PMID: 20067776; PMCID: PMC2834878.
1: Wild A, Winter A, Hager MD, Görls H, Schubert US. Perfluorophenyl-terpyridine ruthenium complex as monomer for fast, efficient, and mild metallopolymerizations. Macromol Rapid Commun. 2012 Apr 13;33(6-7):517-21. doi: 10.1002/marc.201100711. Epub 2012 Jan 27. PMID: 22282016.
2: Wang WG, Wang HY, Si G, Tung CH, Wu LZ. Fluorophenyl-substituted Fe-only hydrogenases active site ADT models: different electrocatalytic process for proton reduction in HOAc and HBF4/Et2O. Dalton Trans. 2009 Apr 21;(15):2712-20. doi: 10.1039/b818012a. Epub 2009 Feb 18. PMID: 19333494.
3: Coburn RA, Batista AJ, Evans RT, Genco RJ. Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus. J Med Chem. 1981 Oct;24(10):1245-9. doi: 10.1021/jm00142a023. PMID: 7328586.
4: Mühlemann HR. Chlorhexidine, Vantocil, Fluorophene and antimycotic agents in an animal caries test. Helv Odontol Acta. 1973 Oct;17(2):99-103. PMID: 4744911.
5: Tikus HW. Topical gels containing Chlorhexidine, Vantocil, Fluorophene and animal caries. Helv Odontol Acta. 1973 Oct;17(2):105-8. PMID: 4744906.
6: de Souza CP, Paulini E. Ação moluscicida do fluoropheno e diapheno em presença de sólidos suspensos na agua [Molluscacide action of fluorophene and diaphene in the presence of solids in water suspension]. Rev Bras Malariol Doencas Trop. 1971 Jan-Dec;23(1):41-9. Portuguese. PMID: 5170693.
